Saturday 17 October 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.9% and free cash flow fell 600.4%, each against the same quarter a year earlier.
1.70
0.17
−9.09%
Follow CNTN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.29 | 1.54 | 6.03 | 5.84 | 0.14 | 0.11 | 0.04 | — |
Net Debt/EBITDA |
0.85 | 0.29 | 1.16 | 1.23 | (0.30) | (0.66) | (0.93) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 124.32% | 436.53% | 2,355.50% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | (0.16) | (0.35) | (0.59) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.45 | 0.89 | 0.78 | 0.77 | 0.49 | 0.45 | 0.46 | — |
Capex/Depreciation |
0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — |
Interest Coverage |
(710.46) | (907.58) | (573.04) | (4.32) | (3.86) | (7.34) | (26.48) | — |
| (17.99%) | (233.70%) | (127.01%) | (1,973.27%) | 52.52% | 90.54% | 57.14% | — | |
| (13.74%) | (166.32%) | (105.69%) | (231.82%) | (481.53%) | (1,440.21%) | (7,459.66%) | — | |
ROIC |
(3.30%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(254.73%) | (932.82%) | (102.06%) | (152.85%) | 56.41% | 99.46% | 140.03% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(2.92) | (8.41) | (83.91) | (217.15) | (63.89) | (63.81) | (1.71) | — |
Cash per Share |
0.53 | 2.75 | 125.69 | 215.58 | 0.26 | 11.36 | 0.09 | — |
Shareholders Equity per Share |
12.42 | 1.01 | 104.96 | 183.57 | (275.58) | (219.97) | (3.94) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
12.42 | 1.01 | 104.96 | 183.57 | (275.58) | (219.97) | (3.94) | — |
Free Cash Flow |
(93.70) | (10.90) | (7.30) | (6.56) | (1.09) | (1.08) | (0.71) | — |
Working Capital |
14.10 | 1.31 | 9.13 | 5.54 | (3.91) | (2.43) | (1.09) | — |
Capital Expenditures |
(77.57) | — | — | — | — | — | — | — |
Net Current Asset Value |
(103.83) | 1.31 | 9.13 | 5.54 | (4.68) | (3.72) | (1.62) | — |
| Other line items | ||||||||
Quick Ratio |
5.18 | 1.47 | 6.03 | 5.69 | 0.00 | 0.07 | 0.03 | — |
Depreciation/Fixed assets |
— | — | — | 0.00 | 0.00 | 0.00 | — | — |
Cash ROIC |
(22.58%) | (224.00%) | (36.38%) | (54.40%) | 27.80% | 48.17% | 113.80% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.50) | (8.41) | (83.91) | (217.15) | (63.89) | (63.81) | (1.71) | — |
Capex per Share |
(2.42) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.09 | 1.00 | 0.93 | 1.21 | 0.99 | — | — | — |
Average Assets |
261.43 | 7.33 | 8.82 | 3.66 | 0.46 | 0.17 | 0.02 | — |
Average Common Equity |
199.62 | 5.22 | 7.34 | 0.43 | (4.20) | (2.67) | (2.67) | — |
Capex to Sales |
0.00 | — | — | — | — | — | — | — |
Columns are period end dates